Product/Composition:- | Ciprofloxacin Oral Tablets |
---|---|
Strength:- | 250 mg, 500 mg, 750 mg |
Form:- | Tablet |
Reference Brands:- | Cipro(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication. This prevents bacterial growth and leads to cell death. It effectively treats urinary, respiratory, and gastrointestinal infections. Benefits include rapid, broad-spectrum activity, good tissue penetration, and convenient oral dosing for effective infection management.
Ciprofloxacin tablets are approved in the EU and US for treating urinary, respiratory, skin, and gastrointestinal infections. In the EU, brands like Cipro are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval relies on extensive clinical data; generics are widely available. Both regions require detailed dossiers, including clinical trial results, manufacturing standards, and pharmacovigilance plans for approval and safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support seamless market access for ciprofloxacin, ensuring adherence to European and American standards for safe, effective antibiotic therapy in diverse infections.